Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Alexion gets exclusive option to Stealth's elamipretide

Executive Summary

Alexion Pharmaceuticals Inc. received the exclusive option to co-develop and commercialize Stealth BioTherapeutics Corp.’s subcutaneous elamipretide in the US for primary mitochondrial myopathy (PMM), Barth syndrome, and Leber’s hereditary optic neuropathy (LHON).
Deal Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies